Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

Eli Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

Shots:

  • The P-III SEQUOIA study involves assessing of Pegilodecakin + Folfox (folinic acid, 5-FU, oxaliplatin) vs Folfox as monothx. in 567 patients with metastatic adenocarcinoma of the pancreas with diseases progression on one prior gemcitabine-containing regimen
  • The P-III SEQUOIA study did not meet its 1EPs of overall survival. Lilly gained Pegilodecakin following the acquisition of ARMO BioSciences in Jun’2018
  • Pegilodecakin is a pegylated IL-10, stimulating the body’s natural defenses against cancer and expands tumor-attacking T cells and has shown clinical activity as monothx. or in combination with CT & with checkpoint inhibitor across multiple cancer indications in P-I/Ib IVY study

Click here to­ read full press release/ article | Ref: Eli Lilly | Image:FinChannel